Dr. Marcus Hompesch is Chief Executive Officer and Chairman of the Board of ProSciento and has led the company since its inception in 2003. He is also editor-in-chief of the journal Endocrinology, Diabetes & Metabolism, a Wiley publication. His career and track record in metabolism-focused clinical R&D, spanning more than 25 years in academic and industry settings, includes contributions to clinical development strategies and early phase research studies for many of the diabetes and related metabolic drugs and devices on the market globally.

Prior to leading ProSciento, Dr. Hompesch was Chief Operating Officer of Profil Institut für Stoffwechselforschung GmbH and, before that, was founder and Chief Executive Officer of the medical technology company Med.IQ. He is an author of more than 100 publications, including peer-reviewed journals and editorials and is a regular peer reviewer for scientific journals relevant to metabolic diseases. He is also an editor and co-author of the textbook Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development.

As a licensed physician in Europe he received his M.D. from the University of Düsseldorf, Germany, and following medical school trained in internal medicine and diabetology at the Klinikum Wuppertal Medical Center. He also was a scientific associate at the Department of Medical Informatics, Bio-Statistics and Epidemiology at the Ruhr University Bochum, Germany.

David Sockolof is the Chief Financial Officer at ProSciento, Inc. Mr. Sockolof is a finance and operations executive with deep experience in corporate growth strategies. His career within the clinical research industry spans more than 20 years, including his role as Executive Director of Resource and Process Optimization at Labcorp Drug Development where he provided leadership in financial forecasting, expense management, and global resource management.

Prior to his position at Labcorp, Mr. Sockolof held a number of leadership roles at PRA Health Sciences, including Vice President of Finance and Business Operations and, prior to that, Director of Business Operations. During his tenure at PRA, his contributions were instrumental in the company’s evolution from a mid-size company to a leading global CRO, including the implementation of strategic financial frameworks and improved systems for proposals and pricing, project finance and global vendor management.  He received his MBA from George Washington University.

Dana Wilkins currently holds the role of Chief Operating Officer (COO) at ProSciento. Before taking on this position, she served as the Vice President of Quality and Regulatory Compliance. With a distinguished career spanning more than 25 years, Ms. Wilkins has established herself as a renowned expert in clinical research operations, regulatory compliance, and quality management systems.

Prior to joining ProSciento, Ms. Wilkins served as the Executive Director of Quality Assurance at Rho, Inc. In this role, she played a pivotal part in crafting an advanced quality management system. Her contributions were highlighted by the establishment of a Quality Board and the implementation of robust processes, fostering a culture of quality across every phase of project development.

Ms. Wilkins’ career history also includes significant roles at BioMerieux, Inc., a leader in in-vitro diagnostics. Here, she held various quality leadership positions, including Global Director of Clinical Operations and the vital role as a Global Quality Board member. In this capacity, she was tasked with upholding and elevating quality standards throughout the realms of Medical Affairs, Clinical Affairs, and Regulatory Affairs. Ms. Wilkins’ leadership played a pivotal role in steering the FDA’s groundbreaking achievement—the clearance of the first 510k IVD product based on meta-analysis. Before her tenure at BioMerieux, she served as the Director of Clinical Research Operations at Lehigh Valley Health Network. Ms. Wilkins is a registered nurse and completed an M.S. in Health Services Administration from the University of St. Francis.

Helge Guenther is ProSciento’s Chief Information Officer. His experience in IT and technology solutions spans more than 20 years, including management of IT operations in highly regulated environments.

Prior to joining ProSciento, Mr. Guenther served as CEO of BIT Group USA and CIO of BIT Group Global, where he oversaw the expansion and optimization of global IT operations. Before that, Mr. Guenther was IT Director at Quest Diagnostics, where he focused on implementing new business solutions in close collaboration with the company’s operations and R&D departments. Prior to his role at Quest Diagnostics, Mr. Guenther was Global Program Manager at Baxter Bioscience, where he oversaw the implementation of Enterprise Resource Planning and related business systems across the company’s locations globally. Mr. Guenther earned his MBA from the University of Duesseldorf, Germany.

Mr. Hernandez is Vice President of ProSciento’s Clinical Research Unit. He is an expert in the field of metabolic clinical research and one of the foremost experts in glucose clamp methodologies and digital wearable technologies for the conduct of clinical trials.

As a Vice President, Moises leads the company’s state-of-art, early phase clinical research unit (CRU) in Chula Vista, CA, and is responsible for overseeing principal investigators, site operations, pharmaceutical services, clinical study management, and ensuring compliance with regulatory requirements. With over 15 years of experience at the company, he has contributed to more than 300 clinical research studies for metabolic therapeutics and devices and has been a member of the company’s senior leadership team for more than eight years, helping to manage company initiatives at a corporate level. He received his Bachelor of Medicine degree from the Universidad Autónoma de Baja California.

Mr. Ustick is Vice President of Global Business Development at ProSciento, Inc. His career in clinical research and business development spans more than 16 years, including nearly 10 years focused on metabolic drug and device development at ProSciento. Casey has held a number of leadership roles within clinical research, including clinical operations, regulatory drug development strategy, budgeting & contracting, and business development, which has provided him a holistic perspective of both operational and business fundamentals in early phase clinical drug development.

During his tenure at ProSciento, Casey has worked with more than 50 sponsors worldwide to help launch their early phase clinical research programs. He has also been instrumental in the company’s global expansion of CRO business initiatives, including expansion of phase 1 clinical activities in Australia, sponsor utilization of NASH PASS® patient access platform, and establishing strategic partnerships with key APAC sponsors. Prior to joining ProSciento, Casey worked at Sessions Plastic Surgery Centre where he received his initial clinical research experience overseeing the site’s contribution to FDA approval of silicone gel-filled implants in 2006. He received his bachelor’s degree from the University of California San Diego.